Trial Profile

First-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer, Coupled to Extensive Translational Studies

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Osimertinib (Primary)
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms FIOL

Most Recent Events

06 May 2024 Planned End Date changed from 31 Aug 2023 to 31 Dec 2025.
06 May 2024 Planned primary completion date changed from 31 Aug 2023 to 1 Jun 2025.
11 Apr 2024 This trial has been completed in Denmark (End Date: 1 Jul 2021), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com